
Photo taken from: Agenus/LinkedIn
Oct 11, 2023, 22:39
Agenus completed the planned patient enrollment of its Phase 2 clinical trial evaluating investigational agents botensilimab (BOT) and balstilimab (BAL) in advanced colorectal cancer. – Agenus
Agenus, made the following post on LinkedIn:
“Agenus completed the planned patient enrollment of its Phase 2 clinical trial evaluating investigational agents botensilimab (BOT) and balstilimab (BAL) in advanced colorectal cancer.”
For details click here.
Source: Agenus/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 29, 2025, 04:16
Mar 28, 2025, 20:11
Mar 28, 2025, 19:58
Mar 28, 2025, 19:38